EEE32 · DCL0035

Formulation & Performance

Formulation & Performance

The study uses EEE and oligonucleotide cell treatments. No LNP assembly recipe, component molar ratios, N/P or lipid:RNA ratio applies to these assays. No study-prefilled lipid component calculator is provided.

N/PNot applicable: cell co-treatment
Lipid:RNANot applicable: cell co-treatment

pKa and N/P

A measured molecular pKa for this compound was not reported in the examined paper and supporting information.

Main paper and SI, Results and Materials and methods · Estupiñán et al., 2025 · DOI: 10.1016/j.omtn.2025.102522

Cell performance

SSO and cell-tolerance assays

In HeLa_Luc705 cells, EEE32 retained SSO-enhancing activity similar to EEE4 in the reported assay. Figure 3A: 1 µM SSO, EEE concentration series, 24-h EEE exposure.

WST-1 and LDH assays showed a more favourable profile than EEE4 at some tested doses/time points. This does not establish general safety.

Figure 3A and corresponding Results/Methods · Estupiñán et al., 2025 · DOI: 10.1016/j.omtn.2025.102522

Primary hepatocyte siRNA assay

Primary human hepatocytes: the paper reports siPPIB + EEE32 IC50 10 nM versus 9 nM for GalNAc-siPPIB, with 2 µM EEE32 in the main protocol. Similar estimates do not establish equivalence. EEE32 also enhanced GalNAc-siPPIB activity and siSOD1 knockdown.

siRNA sampling: Methods specify harvest 72 h after treatment start; the Figure 5 caption states 48 h. Both source statements are retained.

Figure 5A; Results, EEE32 as a multimodal oligonucleotide therapeutics enhancer · Estupiñán et al., 2025 · DOI: 10.1016/j.omtn.2025.102522

DC Chemicals supplies the compound only. Literature results apply to the cited cells, cargo and experimental conditions and do not guarantee performance in another experiment or delivery system.

Animal performance

No animal administration experiment or animal protocol for these compounds was reported in the examined paper and supporting information.

Entire main paper and supporting information · Estupiñán et al., 2025 · DOI: 10.1016/j.omtn.2025.102522

Original literature performance figures

Original Figure 3: A, SSO reporter activity; B, WST-1/LDH at 1 and 24 h. EEE4 and EEE32 groups are labelled; the other analogues remain as comparators. Bars: mean and SD.
Original Figure 3: A, SSO reporter activity; B, WST-1/LDH at 1 and 24 h. EEE4 and EEE32 groups are labelled; the other analogues remain as comparators. Bars: mean and SD. Estupiñán et al., 2025. CC BY 4.0. Original data, axes and statistical marks retained.
Open full-size original figure

Figure 3; article PDF page 6 · Estupiñán et al., 2025 · DOI: 10.1016/j.omtn.2025.102522

Original Figure 5: primary human hepatocyte siRNA experiments. EEE32 evidence is in A-D; EEE4 comparison is in C. RNA-yield heatmap: average of three replicates. Bars: mean and SD. Sampling-time qualification is given above.
Original Figure 5: primary human hepatocyte siRNA experiments. EEE32 evidence is in A-D; EEE4 comparison is in C. RNA-yield heatmap: average of three replicates. Bars: mean and SD. Sampling-time qualification is given above. Estupiñán et al., 2025. CC BY 4.0. Original data, axes and statistical marks retained.
Open full-size original figure

Figure 5; article PDF page 8 · Estupiñán et al., 2025 · DOI: 10.1016/j.omtn.2025.102522

Cell experiment protocol

Stock preparation and final well volume are incompletely reported; this is a partial literature method.

SSO and cell-tolerance assays

  1. Culture HeLa_Luc705 in DMEM + 10% FBS; seed 10000 cells/well in 96-well plates. The general method uses 24-h SSO pretreatment; Figure 3A uses 1 µM SSO.
  2. Apply EEE32 at the Figure 3 concentrations (0.5-5 µM). Figure 3A displays a 24-h EEE readout; toxicity was examined separately at 1 and 24 h.
  3. PBS rinse; lyse in 30 µL 0.1% Triton X-100. Add 30 µL luciferin substrate and read with GloMax: 10-s exposure, 2-s delay. SSO-only and untreated controls are retained; the general LF2000 positive control uses 100-200 nM SSO.
  4. Measure conditioned-medium LDH with a 0.1% Triton positive control, and WST-1 with the reported 4-h preincubation (420-480 nm). Normalize to untreated control.
EEE stock

EEE stock solvent and concentration were not reported.

RNA aqueous phase

705-SSO was supplied/stored in IDTE (10 mM Tris, 0.1 mM EDTA); stock oligonucleotide concentration was not reported.

Mixing and dilution

Cell treatment; no LNP organic/aqueous mixing or assembly procedure.

Final treatment / administration

Final concentrations are given in the protocol below. Final treatment volume per well was not reported.

EEE32: 0.5-5 µM · DMEM + 10% FBS
Storage and use

EEE stock storage temperature, shelf life and freeze-thaw conditions were not reported.

Materials and methods, Oligonucleotide therapeutics functional delivery assessment, Splice-switching oligonucleotide; Cell toxicity assays; Figure 3A-B · Estupiñán et al., 2025 · DOI: 10.1016/j.omtn.2025.102522

MALAT1 antisense assay

  1. Culture N2a in DMEM + 10% FBS; seed 20000 cells/well in 96-well plates.
  2. Cotreat the Figure 4C MALAT1 gapmer series with EEE32 2.5 µM for 24 h.
  3. Extract RNA (Maxwell RSC simplyRNA), quantify (Quant-iT), generate cDNA and perform TaqMan qPCR; use 36B4 as housekeeping control. Compare with gapmer alone.
EEE stock

EEE stock solvent and concentration were not reported.

RNA aqueous phase

Oligonucleotide stock solvent/buffer and stock concentration were not reported.

Mixing and dilution

Cell treatment; no LNP organic/aqueous mixing or assembly procedure.

Final treatment / administration

Final concentrations are given in the protocol below. Final treatment volume per well was not reported.

EEE32: 2.5 µM · DMEM + 10% FBS
Storage and use

EEE stock storage temperature, shelf life and freeze-thaw conditions were not reported.

Materials and methods, Antisense oligonucleotide; Results, EEE32 as a multimodal oligonucleotide therapeutics enhancer; Figure 4C · Estupiñán et al., 2025 · DOI: 10.1016/j.omtn.2025.102522

Primary hepatocyte siRNA assay

  1. Day 0: plate BioIVT QNT primary human hepatocytes on rat-tail collagen I-coated 96-well plates, using Williams E Medium and thawing/plating supplements.
  2. Maintain in Williams E Medium + CM4000 and 5C (DAPT, SB431542, forskolin, IWP2, LDN193189), at 37 °C/5% CO2. Seeding density and exact supplement concentrations were not specified.
  3. Day 1: treat with the study-specific PPIB/SOD1 duplex or GalNAc-siRNA and 2 µM EEE. Figure 5C is a separate 10-nM siPPIB/EEE titration. EEE4 evidence is limited to that comparison.
  4. Change medium at 24 h. Methods specify day-4 harvest (72 h after treatment start); the Figure 5 caption states 48 h.
  5. Extract RNA (RNeasy Micro), generate cDNA, quantify PPIB/SOD1 by TaqMan qPCR with GAPDH control. Include siRNA-only, GalNAc-siRNA and untreated/PBS controls; monitor RNA yield.
EEE stock

EEE stock solvent and concentration were not reported.

RNA aqueous phase

Oligonucleotide stock solvent/buffer and stock concentration were not reported.

Mixing and dilution

Cell treatment; no LNP organic/aqueous mixing or assembly procedure.

Final treatment / administration

Final concentrations are given in the protocol below. Final treatment volume per well was not reported.

EEE32: 2 µM · Williams E + CM4000 + 5C
Storage and use

EEE stock storage temperature, shelf life and freeze-thaw conditions were not reported.

Materials and methods, siRNA; Results, EEE32 as a multimodal oligonucleotide therapeutics enhancer; Figure 5A-D · Estupiñán et al., 2025 · DOI: 10.1016/j.omtn.2025.102522

Animal experiment protocol

No animal administration experiment or animal protocol for these compounds was reported in the examined paper and supporting information.

Entire main paper and supporting information · Estupiñán et al., 2025 · DOI: 10.1016/j.omtn.2025.102522

References

Main article; Figures 3-5; SI Table S1 · Estupiñán et al., 2025 · DOI: 10.1016/j.omtn.2025.102522